Biogen Pharmachem Intrinsic Value
BIOGEN • Financial Services
Current Stock Price
₹0.51
Primary Intrinsic Value
₹1.27
Market Cap
₹3.3 Cr
+149.0%
Upside
Median Value
₹1.27
Value Range
₹0 - ₹1
Assessment
Trading Below Calculated Value
Safety Margin
59.8%
BIOGEN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1.27 | ₹1.14 - ₹1.40 | +149.0% | Book Value/Share: ₹14.15, P/B: 0.8x |
| Revenue Multiple Method | revenue | ₹0.46 | ₹0.41 - ₹0.51 | -9.8% | Revenue/Share: ₹0.46, P/S: 1.0x |
| EBITDA Multiple Method | earnings | ₹1.02 | ₹0.92 - ₹1.12 | +100.0% | EBITDA: ₹3.00Cr, EV/EBITDA: 5x |
| Simple DCF (5Y) | dcf | ₹1.27 | ₹1.02 - ₹1.52 | +149.0% | CF Growth: 5.0%, Discount: 15% |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
BIOGEN Intrinsic Value Analysis
What is the intrinsic value of BIOGEN?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Biogen Pharmachem (BIOGEN) is ₹1.27 (median value). With the current market price of ₹0.51, this represents a +149.0% variance from our estimated fair value.
The valuation range spans from ₹0.46 to ₹1.27, indicating ₹0.46 - ₹1.27.
Is BIOGEN undervalued or overvalued?
Based on our multi-method analysis, Biogen Pharmachem (BIOGEN) appears to be trading below calculated value by approximately 149.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 3.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.03x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Biogen Pharmachem
Additional stock information and data for BIOGEN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-1 Cr | ₹-18 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹4 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |